Physician profile
David Kim
NPI 1073530523
$3,177.95
in general payments reported to CMS, 2019-2025
19 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $122 · 2020: $142 · 2021: $433 · 2022: $713 · 2023: $343 · 2024: $1,006 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,078 · Travel and Lodging: $690.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,078.30 |
| Travel and Lodging | $690.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $732.23 | 2024 | Iovera |
| Stryker Corporation | $602.52 | 2022 | |
| Gilead Sciences, INC. | $304.88 | 2021-2023 | Vemlidy |
| Alexion Pharmaceuticals, INC. | $234.24 | 2025 | |
| Abbott Laboratories | $185.66 | 2021-2025 | Eterna, Ionicrf |
| Pfizer INC. | $157.81 | 2019-2021 | |
| Spr Therapeutics, INC | $139.64 | 2024 | Sprint Pns System |
| Medtronic, INC. | $135.98 | 2021 | |
| Dexcom, INC. | $134.07 | 2024 | Dexcom G7 Gss (161) |
| Novo Nordisk INC | $124.06 | 2021 | |
| Amgen INC. | $121.86 | 2023 | Evenity |
| Astrazeneca Pharmaceuticals Lp | $96.45 | 2023 | Farxiga |
| Medtronic USA, INC. | $90.83 | 2020 | |
| Boston Scientific Corporation | $38.75 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $21.44 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $19.59 | 2020 | |
| Collegium Pharmaceutical, INC. | $16.25 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.24 | 2022 | |
| Fidia Pharma USA INC. | $8.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.